<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336316">
  <stage>Registered</stage>
  <submitdate>8/12/2010</submitdate>
  <approvaldate>10/12/2010</approvaldate>
  <actrnumber>ACTRN12610001084077</actrnumber>
  <trial_identification>
    <studytitle>Comparison of different medications for the control of pain after tonsils and adenoid surgery.</studytitle>
    <scientifictitle>Comparative, prospective, and randomized study of tonsillectomy/adenotonsillectomy post-operative pain control in children.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Post-operative pain control after tonsillectomy/adenotonsillectomy</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>During the 7 days after tonsillectomy/adenotonsillectomy, children between 4-10 years will receive either analgesic alone as necessary (dipyrone - 20mg/kg/dose - or acetaminofen - 15mg/kg/dose, up to 4 times a day, oral drops) or analgesics combined with amoxicilin (50mg/kg/day, 3 times a day for 7 days, oral suspension), prednisolone (0.5mg/kg/day once a day for 7 days, oral solution), ibuprofen (15mg/kg/day, divided in 3 times a day for 7 days, oral drops) or amoxicilin+prednisolone for 7 days.</interventions>
    <comparator>Children will receive analgesics (dipyrone -20mg/kg/dose- or acetaminofen- 15mg/kg/dose) as necessary, up to 4 times a day each. Dipyrone will prefferentially be administered, unless there is history of allergy to dipyrone or there is need of pain control between the intervals of dipyrone use - in these situations, acetaminofen will be used.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Post-operative pain control measured by a clinical questionare that will be fill up by the parents or responsibles (PPP-parents's post-operative pain measure) and by The Faces Pain Scale-Revised filled up by the patient.</outcome>
      <timepoint>7 days after surgery</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluation of side effects with different therapies (diarrhea, abdominal pain, skin rash, bleeding)</outcome>
      <timepoint>7 days after surgery</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Indication for tonsillectomy or adenotonsillectomy
Children between 4-10 years old
Low anaesthesic risk (ASA 1, ASA 2)</inclusivecriteria>
    <inclusiveminage>4</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>10</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Child neuropsycological impairment
Use of medications for chronic pain control
Use of antibiotics or anticoagulants
Perfomance of another concomitant surgery (frenulectomy, ventilation tube insertion, etc)
Allergy to any medication proposed in this study (amoxicilin, prednisolone, ibuprofen)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation will be concealed by contacting the holder of the allocation (principal investigator) by phone, who will be off-site, at the day of the surgery</concealment>
    <sequence>Computed sequence randomization</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/12/2010</anticipatedstartdate>
    <actualstartdate>1/12/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate>29/06/2012</actualenddate>
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Edwin Tamashiro</primarysponsorname>
    <primarysponsoraddress>Av dos Bandeirantes, 3900
Monte Alegre
Ribeirao Preto-SP
CEP 14049-900</primarysponsoraddress>
    <primarysponsorcountry>Brazil</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Faculty of Medicine of Ribeirao Preto - University of Sao Paulo</fundingname>
      <fundingaddress>Avenida dos Bandeirantes, 3900
Monte Alegre
Ribeirao Preto-SP 
CEP 14049-900</fundingaddress>
      <fundingcountry>Brazil</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>FAPESP - Fundacao de Amparo a Pesquisa do Estado de Sao Paulo</fundingname>
      <fundingaddress>R. Pio XI, 1500 - Alto da Lapa - CEP 05468-901 Sao Paulo/SP - Brasil</fundingaddress>
      <fundingcountry>Brazil</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Carolina Brotto de Azevedo</othercollaboratorname>
      <othercollaboratoraddress>Av dos Bandeirantes, 3900
Monte Alegre
Ribeirao Preto-SP
CEP 14049-900</othercollaboratoraddress>
      <othercollaboratorcountry>Brazil</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Danielle Leite Cunha</othercollaboratorname>
      <othercollaboratoraddress>Rua Antonio Deloiagono, 96 ap 41
Vila Ana Maria
Ribeirao Preto-SP
CEP 14026-210</othercollaboratoraddress>
      <othercollaboratorcountry>Brazil</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Lucas Rodrigues Carenzi</othercollaboratorname>
      <othercollaboratoraddress>Av dos Bandeirantes, 3900 Monte Alegre
CEP 14049-900
Ribeirao Preto - SP</othercollaboratoraddress>
      <othercollaboratorcountry>Brazil</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Wilma Terezinha Anselmo-Lima</othercollaboratorname>
      <othercollaboratoraddress>Av dos Bandeirantes, 3900 Monte Alegre
Ribeirao Preto - SP
CEP 14049-900</othercollaboratoraddress>
      <othercollaboratorcountry>Brazil</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Daniel Salgado Kupper</othercollaboratorname>
      <othercollaboratoraddress>Av dos Bandeirantes, 3900 Monte Alegre
Ribeirao Preto - SP
CEP 14049-900</othercollaboratoraddress>
      <othercollaboratorcountry>Brazil</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Fabiana Cardoso Pereira Valera</othercollaboratorname>
      <othercollaboratoraddress>Av dos Bandeirantes, 3900 Monte Alegre
Ribeirao Preto - SP
CEP 14049-900</othercollaboratoraddress>
      <othercollaboratorcountry>Brazil</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Tonsillectomy and Adenotonsillectomy are the main surgeries performed in children worlwide. However, there is no consensus on how is the best way to manage pain after surgery in these cases. In this study, our primary goal will be to investigate if the additional use of antibiotics (amoxicilin), non-esteroidal antiinflammatory (ibuprofen) or corticosteroid (prednisolone) can change the history of pain that follows these surgeries. Additionally, we will also investigate if the use of these drugs in the post-operative period leads to adverse effects. Finally, we will balance the risk/benefit use of these drugs in the post-operative time of tonsillectomy/adenotonsillectomy in children.</summary>
    <trialwebsite />
    <publication>Azevedo CB, Carenzi LR, Queiroz DLC, Anselmo-Lima WT, Valera FC, Tamashiro E. Clinical utility of PPPM and FPS-R to quantify post-tonsillectomy pain in children. Int J Pediatr Otorhinolaryngol. 2014 Feb;78(2):296-9. doi: 10.1016/j.ijporl.2013.11.027.27/11/2013</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Human Research Ethics Comittee of the Hospital of Clinics of the Faculty of Medicine of Ribeirao Preto -USP</ethicname>
      <ethicaddress>Av dos Bandeirantes, 3900
Monte Alegre
Ribeirao Preto-SP
CEP 14049-900</ethicaddress>
      <ethicapprovaldate>4/10/2010</ethicapprovaldate>
      <hrec>9838/2010</hrec>
      <ethicsubmitdate />
      <ethiccountry>Brazil</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Edwin Tamashiro</name>
      <address>Av dos Bandeirantes, 3900
Monte Alegre
Ribeirao Preto-SP
CEP 14049-900</address>
      <phone>55-16-3602-2863</phone>
      <fax />
      <email>edwin@fmrp.usp.br</email>
      <country>Brazil</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Edwin Tamashiro</name>
      <address>Av dos Bandeirantes, 3900
Monte Alegre
Ribeirao Preto-SP
CEP 14049-900</address>
      <phone>55-16-3602-2863</phone>
      <fax />
      <email>edwin@fmrp.usp.br</email>
      <country>Brazil</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Edwin Tamashiro</name>
      <address>Av dos Bandeirantes, 3900
Monte Alegre
Ribeirao Preto-SP
CEP 14049-900</address>
      <phone>55-16-3602-2863</phone>
      <fax />
      <email>edwin@fmrp.usp.br</email>
      <country>Brazil</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Edwin Tamashiro</name>
      <address>Ribeirao Preto School of Medicine
University of Sao Paulo
Av dos Bandeirantes, 3900 Monte Alegre
Ribeirao Preto - SP - Brazil
CEP 14049-900</address>
      <phone>55-16-36022863</phone>
      <fax />
      <email>edwintamashiro@yahoo.com.br</email>
      <country>Brazil</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>